ADL5859

Known as: ADL 5859, ADL-5859 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
0120082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION Opioids are widely used to treat severe pain. Most clinically used opioids activate µ-opioid receptors (MOR). Their… (More)
Is this relevant?
2016
2016
Kappa opioid (KOP) receptor antagonists and delta opioid (DOP) receptor agonists have antidepressant-like effects in animal tests… (More)
Is this relevant?
2015
2015
The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat… (More)
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BACKGROUND AND PURPOSE Activation of δ opioid (DOP) receptors regulates pain and emotional responses, and also displays ligand… (More)
Is this relevant?
2013
2013
Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4… (More)
Is this relevant?
2009
2009
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents… (More)
Is this relevant?
2008
2008
Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain… (More)
Is this relevant?